Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Cohesive Bandage Fixation of Pulse Oximeter Probes and Skin Condition in Preterm Neonates

NCT07864298 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-10
Last updated
2026-10-07

Condition(s) studied

Skin InjuryPremature BirthMedical Adhesive Related Skin Injury

Investigational drug(s) / intervention(s)

Cohesive bandage fixation of pulse oximeter probeStandard adhesive fixation of pulse oximeter probe

Cohesive bandage fixation of pulse oximeter probe: The adhesive surface of the pulse oximeter probe is attached to a latex-free cohesive bandage (5 cm wide, length 1.5 times the circumference of the site) with openings matching the emitter and detector windows. The bandage ends adhere only to each other, so no adhesive contacts the skin. Wrap tension is checked with a capillary refill test.

Standard adhesive fixation of pulse oximeter probe: The pulse oximeter probe is applied directly to the skin with its original adhesive according to routine practice and manufacturer instructions.

Study summary

Pulse oximeter probes are used to continuously monitor oxygen levels in newborn babies in intensive care. These probes are usually attached to the baby's hand or foot with adhesive tape and must be moved to a new site every few hours. Repeatedly sticking and removing adhesive can damage the delicate skin of premature babies.

The investigators have developed a new way to secure the probe without any adhesive touching the skin: the probe's adhesive side is attached to a soft, self-adhering (cohesive) bandage that wraps around the baby's hand or foot. The bandage sticks only to itself, not to the skin.

The purpose of this study is to find out whether securing the probe with a cohesive bandage protects the skin better than the standard method of taping the probe directly to the skin. Sixty-four premature babies (born at 32 to 36 weeks) will be randomly placed in one of two groups. In both groups, the probe will be placed on each hand and foot for four hours in turn, for a total of 16 hours. The skin under the probe will be photographed and scored by two nurses who do not know which method was used.

Eligibility

Sex
ALL
Min age
0 Years
Max age
28 Days
Healthy volunteers
No
Inclusion Criteria: * Gestational age 32 0/7 to 36 6/7 weeks * Birth weight 1500 g or more * Requiring continuous pulse oximetry monitoring, expected to last at least 16 hours * No primary skin lesion, congenital anomaly or active dermatological disease * Written informed consent from a parent Exclusion Criteria: * Hydrops fetalis or generalized peripheral edema * Systemic corticosteroid, immunosuppressive or vasoactive drug use * Impaired peripheral circulation in the extremities to be used for probe application * Skin changes due to uremia or cholestasis * Receiving phototherapy or topical pharmacological application to the skin * Receiving sedation

Primary outcome measure(s)

  • Neonatal Skin Condition Score (NSCS) total score at the probe application site — 30 minutes after probe removal at the end of each 4-hour application (up to 16 hours)
    Skin condition at each probe application site is assessed with the Neonatal Skin Condition Score adapted to the probe site. The score includes three items (dryness, erythema, skin breakdown), each scored from 1 to 3; the total score ranges from 3 (best) to 9 (worst). Scoring is performed on standardized photographs by two independent observers blinded to group allocation, and the mean of the two observers' scores is used.

Trial sites (1)

FacilityCityRegionStatus
Uskudar University Istanbul Istanbul
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864298 on ClinicalTrials.gov ↗ ← All trials in Turkey